About
AEON Biopharma, Inc.
AEON.US
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc.
Profile
- Company Name
- AEON Biopharma, Inc.
- Market
- NYSEAM
- Founded
- --
- Industry
- --
- Fiscal Year End
- December 31
- Website
- www.aeonbiopharma.com